multiglycosidorum tripterygii

immunosuppressant extracted from Tripterygium Wilfordii Hook-F (TW) and refined repeatedly; it chiefly contains glycosides with stable quality and has less side effects than other crude extracts of TW

Also Known As:

Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Choi, Hae-Yun: 2 articles (08/2010 - 12/2008)
2.	Kim, Jong-Dae: 2 articles (08/2010 - 12/2008)
3.	Ku, Sae-Kwang: 2 articles (08/2010 - 12/2008)
4.	Lee, Hyeung-Sik: 2 articles (08/2010 - 12/2008)
5.	Park, Mee-Yeon: 2 articles (08/2010 - 12/2008)
6.	Dai, Xingbin: 1 article (05/2017)
7.	Ji, Yanhua: 1 article (05/2017)
8.	Jiang, Pengjun: 1 article (05/2017)
9.	Sun, Xuemei: 1 article (05/2017)
10.	Arancibia-Avila, Patricia: 1 article (03/2012)

Related Diseases

1.	Coronary Artery Disease (Coronary Atherosclerosis) 06/15/1998 - "Inhibitory effect of Multiglycosidorum tripterygii on coronary arteriosclerosis after heart transplantation." 03/01/1999 - "Multiglycosidorum tripterygii, a new immunosuppressant, supresses coronary arteriosclerosis after heart transplantation." 03/01/1999 - "In this study, we investigate the effect of multiglycosidorum tripterygii on graft coronary arteriosclerosis and platelet-derived growth factor A mRNA expression of transplanted hearts. " 03/01/1999 - "Multiglycosidorum tripterygii is superior to cyclosporine in prevention and attenuation of graft coronary arteriosclerosis and this efficacy is probably associated with the depressed expression of graft platelet-derived growth factor A mRNA in the multiglycosidorum tripterygii-treated groups."
2.	Lymphoma (Lymphomas) 05/01/2017 - "In the present study, the effects of MT extract (MTE) on EC proliferation and apoptosis in vitro, and on A20 mouse lymphoma growth and angiogenesis in vivo were investigated. "
3.	Asthma (Bronchial Asthma) 08/01/2010 - "As part of a safety evaluation of MT extract for use in asthma, the 28 day repeat oral dose toxicity of an aqueous MT extract was evaluated at 800, 400 and 200mg/kg per day dose levels. " 12/01/2008 - "As part of a safety evaluation of MT extracts for use in asthma, the potential genotoxicity of an aqueous MT extract was evaluated using the standard battery of tests (bacterial reverse mutation assay; chromosomal aberrations assay; mouse micronucleus assay) recommended by Korea Food and Drug Administration (KFDA). "
4.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 02/01/2004 - "[Treatment of chronic refractory idiopathic thrombocytopenic purpura in children with multiglycosidorum Tripterygii and prednisone]." 02/01/2004 - "In order to determine the curative effect of multiglycosidorum Tripterygii and prednisone for treatment of children with chronic refractory idiopathic thrombocytopenic purpura (ITP), a total of 28 patients had been treated with multiglycosidorum Tripterygii and prednisone. "
5.	Liver Diseases (Liver Disease) 06/01/2011 - "MT extract can effectively prevent methotrexate-induced liver dysfunction and fibrosis in rats."

Related Drugs and Biologics

1.	Messenger RNA (mRNA)
2.	platelet-derived growth factor A
3.	Cyclosporine (Ciclosporin)
4.	Prednisone (Sone)
5.	Methotrexate (Mexate)
6.	Inosine Triphosphate (ITP)
7.	Immunosuppressive Agents (Immunosuppressants)

Related Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart)